Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1272

1.

Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.

Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA.

Diabetes. 2008 Jan;57(1):24-31. Epub 2007 Oct 3.

2.

Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

Miyazaki Y, Mahankali A, Matsuda M, Glass L, Mahankali S, Ferrannini E, Cusi K, Mandarino LJ, DeFronzo RA.

Diabetes Care. 2001 Apr;24(4):710-9.

PMID:
11315836
4.

A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog.

Sindelar DK, Balcom JH, Chu CA, Neal DW, Cherrington AD.

Diabetes. 1996 Nov;45(11):1594-604.

PMID:
8866566
5.

Effects of pioglitazone and metformin on NEFA-induced insulin resistance in type 2 diabetes.

Basu R, Basu A, Chandramouli V, Norby B, Dicke B, Shah P, Cohen O, Landau BR, Rizza RA.

Diabetologia. 2008 Nov;51(11):2031-40. doi: 10.1007/s00125-008-1138-1. Epub 2008 Sep 4.

6.

Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, Cersosimo E, Miyazaki Y, DeFronzo RA.

Diabetes. 2003 Jun;52(6):1364-70.

7.

The effect of pioglitazone on hepatic glucose uptake measured with indirect and direct methods in alloxan-induced diabetic dogs.

Matsuhisa M, Shi ZQ, Wan C, Lekas M, Rodgers CD, Giacca A, Kawamori R, Vranic M.

Diabetes. 1997 Feb;46(2):224-31.

PMID:
9000698
8.

Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes.

Roden M, Mariz S, Brazzale AR, Pacini G.

J Intern Med. 2009 Apr;265(4):476-87. doi: 10.1111/j.1365-2796.2008.02040.x.

9.

Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes.

Gastaldelli A, Casolaro A, Pettiti M, Nannipieri M, Ciociaro D, Frascerra S, Buzzigoli E, Baldi S, Mari A, Ferrannini E.

Clin Pharmacol Ther. 2007 Feb;81(2):205-12.

PMID:
17259945
10.
11.

Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content.

Ravikumar B, Gerrard J, Dalla Man C, Firbank MJ, Lane A, English PT, Cobelli C, Taylor R.

Diabetes. 2008 Sep;57(9):2288-95. doi: 10.2337/db07-1828. Epub 2008 Jun 5.

12.

The effect of pioglitazone on the liver: role of adiponectin.

Gastaldelli A, Miyazaki Y, Mahankali A, Berria R, Pettiti M, Buzzigoli E, Ferrannini E, DeFronzo RA.

Diabetes Care. 2006 Oct;29(10):2275-81.

PMID:
17003306
13.

Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.

Fernandez M, Triplitt C, Wajcberg E, Sriwijilkamol AA, Musi N, Cusi K, DeFronzo R, Cersosimo E.

Diabetes Care. 2008 Jan;31(1):121-7. Epub 2007 Oct 1.

PMID:
17909084
14.

Effect of continuous subcutaneous insulin infusion with lispro on hepatic responsiveness to glucagon in type 1 diabetes.

Launay B, Zinman B, Tildesley HD, Strack T, Chiasson JL.

Diabetes Care. 1998 Oct;21(10):1627-31.

PMID:
9773721
15.

Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.

Miyazaki Y, Matsuda M, DeFronzo RA.

Diabetes Care. 2002 Mar;25(3):517-23.

PMID:
11874940
16.

Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production.

Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB.

Diabetes. 1994 Jul;43(7):920-8.

PMID:
8013758
17.

Improved insulin action and glycemic control after long-term angiotensin-converting enzyme inhibition in subjects with arterial hypertension and type II diabetes.

Torlone E, Britta M, Rambotti AM, Perriello G, Santeusanio F, Brunetti P, Bolli GB.

Diabetes Care. 1993 Oct;16(10):1347-55.

PMID:
8269792
18.
19.
20.

Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects.

Halberstam M, Cohen N, Shlimovich P, Rossetti L, Shamoon H.

Diabetes. 1996 May;45(5):659-66. Erratum in: Diabetes 1996 Sep;45(9):1285.

PMID:
8621019

Supplemental Content

Support Center